Search results for " stimulating"

showing 10 items of 67 documents

Male fertility in long-term survivors of childhood ALL.

1999

A study of fertility was conducted in postpubertal male patients who had been treated for acute lymphoblastic leukemia (ALL) during childhood or adolescence between 1970 and 1980. Thirteen men (age 18 to 35 years) participated on a volunteer basis. Their age at diagnosis was between 2 and 15 years. Therapy followed the protocol ''Memphis VII (Pinkel)." Interview, physical examination, andrological studies (ejaculate), and hormone status (luteinizing hormone, follicle-stimulating hormone, and testosterone) were performed at least 5 years after completion of therapy. No normozoospermia was achieved; 10 patients were identified with asthenozoospermia and 3 patients with azoospermia. With respe…

InfertilityAdultMalePediatricsmedicine.medical_specialtyAdolescentmedia_common.quotation_subjectFertilityAntineoplastic AgentsAsthenozoospermiaFollicle-stimulating hormoneEndocrinologyAcute lymphocytic leukemiamedicineHumansTestosteroneSurvivorsTestosteroneInfertility Malemedia_commonGynecologyAzoospermiaSperm Countbusiness.industryLuteinizing HormonePrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseSpermatozoaFertilitySperm MotilityFollicle Stimulating HormoneLuteinizing hormonebusinessArchives of andrology
researchProduct

Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimula…

2004

The serum LH was determined on days 3, 6, and 8 of stimulation and on the day of hCG in 110 normogonadotropic patients undergoing controlled ovarian hyperstimulation (COH) for IVF induced with GnRH antagonists and recombinant FSH, creating three groups of patients according to Tukey's hinges (percentiles 25 and 75) for each determination. No differences were observed between the number of oocytes recovered or the fertilization, implantation, and pregnancy rates (PR) of the groups, although patients with high serum LH levels during stimulation showed significantly higher serum E2 levels on the day of hCG.

InfertilityAdultendocrine systemmedicine.medical_specialtyAdolescentStimulationGonadotropin-releasing hormoneControlled ovarian hyperstimulationBiologyCohort StudiesGonadotropin-Releasing HormoneFollicle-stimulating hormoneOvulation InductionInternal medicinemedicineHumansProspective StudiesMenstrual CyclePregnancyAntagonistObstetrics and GynecologyLuteinizing Hormonemedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineFemaleFollicle Stimulating Hormone HumanLuteinizing hormoneInfertility Femalehormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Genome-Wide Association Analysis in Primary Sclerosing Cholangitis

2010

Background & Aims We aimed to characterize the genetic susceptibility to primary sclerosing cholangitis (PSC) by means of a genome-wide association analysis of single nucleotide polymorphism (SNP) markers. Methods A total of 443,816 SNPs on the Affymetrix SNP Array 5.0 (Affymetrix, Santa Clara, CA) were genotyped in 285 Norwegian PSC patients and 298 healthy controls. Associations detected in this discovery panel were re-examined in independent case-control panels from Scandinavia (137 PSC cases and 368 controls), Belgium/The Netherlands (229 PSC cases and 735 controls), and Germany (400 cases and 1832 controls). Results The strongest associations were detected near HLA-B at chromosome 6p21…

LOCIMacrophage Stimulating 1 (Hepatocyte Growth Factor-Like)Genome-wide association studySUSCEPTIBILITYGene FrequencyHLA AntigensRisk FactorsHEPATOCELLULAR-CARCINOMAOdds RatioBileBiliary TractINCREASED RISKOligonucleotide Array Sequence AnalysisGastroenterologyMULTIPLE-SCLEROSISCROHNS-DISEASEEuropePhenotypeULCERATIVE-COLITISInflammation MediatorsSNP arrayCholangitis SclerosingSingle-nucleotide polymorphismLocus (genetics)Human leukocyte antigenBiologyPolymorphism Single NucleotideRisk AssessmentCell LinePrimary sclerosing cholangitisGlypicansGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseGene SilencingACID RECEPTOR TGR5Genetic associationInflammationChi-Square DistributionHepatologyGene Expression ProfilingGlypican 6medicine.diseaseGENEG-Protein-Coupled Bile Acid Receptor 1Case-Control StudiesImmunologyColitis UlcerativeGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASEGastroenterology
researchProduct

Gluten-free diet impact on leptin levels in asymptomatic coeliac adolescents: one year of follow-up.

2006

Coeliac disease, daily more frequently diagnosed in our population, involves many organs also in oligosymptomatic patients and with an adequate nutritional regime. Possible endocrine implications include failure to thrive, pubertal delay and reproduction diseases due to deregulation of GH, FSH and LH secretion. Leptin, an adipose tissue hormone, can be decreased as well and its deficiency could be related to growth and puberty anomalies. We studied 14 asymptomatic coeliac patients in peripubertal age (7.5–13.8 years) and tested their leptin levels in order to correlate them with endocrine and anthropometric data. Before the diet was started leptinaemia (M±DS) was: 4.94 ± 5.53 ng/ml. In 10/1…

LeptinMalemedicine.medical_specialtyPediatricsAdolescentGlutensEndocrinology Diabetes and MetabolismPopulationAsymptomaticCoeliac diseaseBody Mass IndexEndocrinologyInternal medicinemedicineEndocrine systemHumanseducationChildeducation.field_of_studybusiness.industryLeptinPubertyLuteinizing Hormonemedicine.diseaseCeliac DiseaseEndocrinologyPediatrics Perinatology and Child HealthGluten freeFemalemedicine.symptomFollicle Stimulating HormonebusinessFollow-Up StudiesHormone research
researchProduct

Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy

2013

Abstract Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically used to treat anemia in patients with cancer receiving chemotherapy. After clinical trials reporting increased adverse events and/or reduced survival in ESA-treated patients, concerns have been raised about the potential role of ESAs in promoting tumor progression, possibly through tumor cell stimulation. However, evidence is lacking on the ability of EPO to directly affect cancer stem–like cells, which are thought to be responsible for tumor progression and relapse. We found that breast cancer stem–like cells (BCSC) isolated from patient tumors express the EPO receptor and respond to …

MAPK/ERK pathwayOncologyCancer Researchmedicine.medical_treatmentFluorescent Antibody TechniqueApoptosisMice SCIDImmunoenzyme TechniquesMiceCell MovementMice Inbred NODhemic and lymphatic diseasesTumor Cells CulturedCulturedBlottingAnemiaFlow CytometryTumor CellsTRIALSOncologyDisease ProgressionNeoplastic Stem CellsFemaleWesternSignal Transductionmedicine.drugSTIMULATING AGENTSEXPRESSIONmedicine.medical_specialtyBlotting WesternAntineoplastic AgentsBreast NeoplasmsSCIDRECOMBINANT-HUMAN-ERYTHROPOIETIN STIMULATING AGENTS EXPRESSION MORTALITY TRIALS ANEMIA ALPHA ALDH1Breast cancerIn vivoInternal medicinemedicineAnimalsHumansBreast cancer Cancer stem cellsALDH1ErythropoietinProtein kinase BCell ProliferationSettore MED/04 - Patologia GeneraleChemotherapybusiness.industryMORTALITYCancerRECOMBINANT-HUMAN-ERYTHROPOIETINmedicine.diseaseALPHAErythropoietinTumor progressionInbred NODAnemia; Animals; Antineoplastic Agents; Apoptosis; Blotting Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Disease Progression; Erythropoietin; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice Inbred NOD; Mice SCID; Neoplastic Stem Cells; Signal Transduction; Tumor Cells Cultured; Cancer Research; Oncologybusiness
researchProduct

Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

2017

Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 6…

MaleCancer Research0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesHydroxyureaCumulative incidenceTreatment FailureEnzyme InhibitorsLenalidomideAged 80 and overCytarabineAnemiaMiddle AgedThalidomideMelodysplastic syndromeSurvival RateLeukemia Myeloid AcuteOncologyInternational Prognostic Scoring System030220 oncology & carcinogenesisRetreatmentAzacitidineCyclosporineDisease ProgressionChromosomes Human Pair 5FemaleChromosome DeletionErythrocyte Transfusionmedicine.drugmedicine.medical_specialtyMelodysplastic syndrome erytropoiesis stimulating agents 5q-erytropoiesis stimulating agentsDecitabineAntineoplastic AgentsTretinoinDecitabineLower risk5q-Arsenic03 medical and health sciencesInternal medicinemedicineHumansImmunologic FactorsSurvival rateAgedAntilymphocyte SerumRetrospective StudiesLenalidomidebusiness.industryValproic AcidMyelodysplastic syndromesRetrospective cohort studymedicine.diseaseMyelodysplastic SyndromesHematinicsPhysical therapybusiness030215 immunology
researchProduct

Experimental Testicular Torsion: Effect on Endocrine and Exocrine Function and Contralateral Testicular Histology

1988

In order to investigate whether unilateral testicular torsion exerts a negative influence on the previously undisturbed contralateral side, exocrine and endocrine testicular function were evaluated before and two months after torsion. A rat model with 6 hours', 12 hours' or permanent extravaginal 540 degrees torsion of the right testis was used; a sham operated group of animals served as controls. Ejaculates were collected by electrostimulation; LH, FSH and testosterone serum levels were determined by radioimmunoassays. Eight weeks after torsion sperm output had decreased by half in the experimental groups, and LH levels increased significantly, whereas the other hormone levels, as well as …

MaleNephrologymedicine.medical_specialtyClinical chemistryUrologyInternal medicineTestisAnimalsMedicineEndocrine systemTesticular torsionTestosteroneSpermatogenesisSpermatic Cord Torsionbusiness.industryTorsion (gastropod)Rats Inbred StrainsRadioimmunoassayLuteinizing Hormonemedicine.diseaseSpermRatsTesticular functionEndocrinologyTesticular histologyFollicle Stimulating HormonebusinessHormoneJournal of Urology
researchProduct

Toxicological Profile of Ultrapure 2,2´,3,4,4´,5,5´-Heptachlorbiphenyl (PCB 180) in Adult Rats

2014

PCB 180 is a persistent non-dioxin-like polychlorinated biphenyl (NDL-PCB) abundantly present in food and the environment. Risk characterization of NDL-PCBs is confounded by the presence of highly potent dioxin-like impurities. We used ultrapure PCB 180 to characterize its toxicity profile in a 28-day repeat dose toxicity study in young adult rats extended to cover endocrine and behavioral effects. Using a loading dose/maintenance dose regimen, groups of 5 males and 5 females were given total doses of 0, 3, 10, 30, 100, 300, 1000 or 1700 mg PCB 180/kg body weight by gavage. Dose-responses were analyzed using benchmark dose modeling based on dose and adipose tissue PCB concentrations. Body w…

MalePhysiologyAdipose tissueTHYROID-HORMONEPOSTNATAL EXPOSURE010501 environmental sciences413 Veterinary scienceToxicologyPathology and Laboratory Medicine01 natural sciencesBiochemistryRats Sprague-DawleyFollicle-stimulating hormoneHemoglobinsMedicine and Health SciencesEFFECT-DIRECTED ANALYSIS0303 health scienceseducation.field_of_studyMultidisciplinaryBehavior AnimalMaintenance doseQRNeurochemistryAnemiaNeurotransmittersHematologyPolychlorinated BiphenylsToxicokineticsAdipose TissueHematocritLiverToxicityBlood ChemistryMedicineEnvironmental PollutantsFemaleLuteinizing hormoneResearch ArticleARYL-HYDROCARBON RECEPTORNeurotoxicologymedicine.medical_specialtyThyroid HormonesPOLYCHLORINATED-BIPHENYLS PCBSScienceeducationPopulationToxic Agentsta3111Loading dose03 medical and health sciencesRetinoidsSex FactorsInternal medicinemedicineSex HormonesDEVELOPMENTAL EXPOSUREAnimalseducationToxic equivalency factorMolecular Biology030304 developmental biology0105 earth and related environmental sciencesToxicityDose-Response Relationship DrugDIBENZO-P-DIOXINSBody WeightBiology and Life SciencesIN-VITROKemiLuteinizing HormoneHormonesRatsDIOXIN-LIKE-PCBSEndocrinologyChemical SciencesAdrenal CortexExploratory BehaviorSUBCHRONIC TOXICITYFollicle Stimulating HormoneDNA Damage
researchProduct

Abnormal thyroid hormones and non-thyroidal illness syndrome in obstructive sleep apnea, and effects of CPAP treatment

2016

Objective In obstructive sleep apnea (OSA), while both hypothyroidism and hyperthyroidism have been studied, the occurrence of non-thyroidal illness syndrome (NTIS) (normal thyroid stimulating hormone [TSH] with low triiodotironine) has not been investigated. We explored the occurrence of NTIS in patients with moderate to severe OSA and its relationship to the severity of nocturnal respiratory disorders. We also studied the occurrence of subclinical hypothyroidism (SH, ie, high TSH with normal thyroxine) in OSA and changes in circulating TSH, free triiodotironine (fT3) and free thyroxine (fT4) after CPAP treatment. Methods After a nocturnal respiratory polysomnography, 125 consecutive patie…

Maleendocrine system diseasesSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOPolysomnographyGastroenterologyHypoxemiaHypoxemia0302 clinical medicineSubclinical hypothyroidismThyroid stimulating hormoneobstructive sleep apneaOxygen saturation (medicine)Subclinical infectionSleep Apnea ObstructiveContinuous Positive Airway Pressuremedicine.diagnostic_testMedicine (all)apnee ostruttive nel sonnoGeneral MedicineMiddle Agedfunzione tiroideaTriiodothyronineFemalemedicine.symptomhormones hormone substitutes and hormone antagonistsThyroid Hormonesendocrine systemmedicine.medical_specialtyPolysomnography03 medical and health sciencesThyroid-stimulating hormoneInternal medicinemedicineHumansthyroid functionbusiness.industrymedicine.diseaseEuthyroid Sick Syndromesrespiratory tract diseasesThyroid hormoneObstructive sleep apneaThyroxineEndocrinology030228 respiratory systemCase-Control Studiesbusiness030217 neurology & neurosurgeryEuthyroid sick syndromeHormoneEuthyroid sick syndromeSleep Medicine
researchProduct

Treatment of cryptorchidism with a potent analog of gonadotropin-releasing hormone.

1978

Pernasal therapy of cryptorchidism with D-Leu6-des-Gly10-gonadotropin-releasing hormone ethylamide (D-Leu6-des-Gly10-GnRH-EA), a potent, long-acting GnRH analog, was attempted. Eleven prepubertal cryptorchid boys received between 25 microgram once daily and 25 to 50 microgram twice daily for 5 to 12 weeks. Complete testicular descent was achieved in 4 of the 11 boys. GnRH tests (1.5 microgram/kg intravenously), conducted in six boys before treatment, after 4 weeks of treatment, and in 2 boys 3 months after treatment, did not reveal changes in gonadotropin secretion indicative of precocious puberty or of decreased hypophyseal sensitivity to GnRH. Antibodies to the GnRH analog or to GnRH coul…

Maleendocrine systemmedicine.medical_specialtyTime FactorsGonadotropin-releasing hormoneInternal medicineCryptorchidismMedicinePrecocious pubertyHumansChildbusiness.industryObstetrics and GynecologyInfantGnRH AnalogLuteinizing Hormonemedicine.diseaseGonadotropin secretionEndocrinologyReproductive MedicineChild PreschoolAntibody FormationOnce dailyFollicle Stimulating HormonebusinessPituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsAfter treatmentGonadotropinsHormoneFertility and sterility
researchProduct